TALDO1 and breast carcinoma: Patients with SLC1A5 + TALDO1 + had the worst outcome and further analysis revealed a significant association between SLC1A5 + TALDO1 + expression and a high risk of recurrence and death from breast cancer in patients who had received adjuvant endocrine therapy only.